Unmet Needs in Endometrial Cancer

Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium. Faculty describe how these agents may fill a meaningful gap in recurrent disease, yet also note that unusual toxicities require rapid clinician education and early intervention if patients are to stay on therapy safely. A major unanswered question is whether one antibody drug conjugate can retain activity after prior exposure to another with a similar payload, especially as more targets become clinically relevant. The conversation also highlights the growing challenge of selecting among multiple biomarkers when a tumor may express several potentially actionable targets at the same time. Beyond the recurrent setting, the faculty consider whether these therapies may eventually move earlier and reduce reliance on more toxic multidrug strategies. That possibility is appealing, but it depends on stronger evidence and better understanding of how to choose the right treatment for the right patient. These issues provide a natural bridge into similar questions arising in ovarian cancer.